New and emerging drugs for the treatment of acne vulgaris in adolescents

References

• Gollnick HP, Bettoli V, Lambert J, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30(9):1480–1490.
   PubMed Web of Science ®Google Scholar
• Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2S1):S1–S23.
   PubMedGoogle Scholar
• Mwanthi M, Zaeglein L. Update in the management of acne in adolescents. Curr Opin Pediatr. 2018;30(4):492–498.
   PubMed Web of Science ®Google Scholar
• Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1–37.
   PubMed Web of Science ®Google Scholar
• Smithard A, Glazebrook C, Williams HC. Acne Prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community based study. Br J Dermatol. 2001;145(2):274–279.
   PubMed Web of Science ®Google Scholar
• Dreno B, Poli F. Epidemiology of acne. Dermatology. 2003;206(1):7–10.
   PubMed Web of Science ®Google Scholar
• Ghodsi Z, Orawa H, Zouboulis C. Prevalence, severity and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol. 2009;129(9):2136–2141.
   PubMed Web of Science ®Google Scholar
• Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–485.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131(Suppl 3):S163–186.
   PubMed Web of Science ®Google Scholar
• Webster GF. The pathophysiology of acne. Cutis. 2005;76(2 Suppl):4–7.
   PubMed Web of Science ®Google Scholar
• Gebauer K. Acne in adolescents. Aust Fam Physician. 2017;46(12):892–895.
   PubMedGoogle Scholar
• Eyuboglu M, Kalay I, Eyoboglu D. Evaluation of adolescents diagnosed with acne vulgaris for quality of life and psychosocial challenges. Indian J Dermatol. 2018;63(2):131–135.
   PubMed Web of Science ®Google Scholar
• Gallitano SM, Berson DS. How acne bumps cause the blues: the influence of acne vulgaris on self-esteem. Int J Womens Dermatol. 2017;4(1):12–17.
   PubMedGoogle Scholar
• Eroglu FO, Aktepe E, Erturan I. The evaluation of psychiatric comorbidity, self‐injurious behavior, suicide probability, and other associated psychiatric factors (lonileness, self‐esteem, life satisfaction) in adolescents with acne: A clinical pilot study. J Cosmet Dermatol. 2018 Jul 11. [Epub ahead of print]. DOI:10.1111/jocd.12708.
   Google Scholar
• Dunn LK, O’Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J. 2011;17(1):1.
   PubMedGoogle Scholar
• Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA. J Drugs Dermatol. 2017;16(2):97–102.
   PubMed Web of Science ®Google Scholar
• Scholz CF, Kilian M. The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov. Int J Syst Evol Microbiol. 2016;66(11):4422–4432.
   PubMedGoogle Scholar
• Thiboutot D, Gollnick H, Bettoli V, et al. Global alliance to improve outcomes in acne. New insights into the management of acne: an update from the global alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60(Suppl 5):S1–50.
   PubMed Web of Science ®Google Scholar
• Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261–1268.
   PubMed Web of Science ®Google Scholar
• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.
   PubMed Web of Science ®Google Scholar
• Nast A, Bayerl C, Borelli C, et al. S2k-guideline for therapy of acne. J Dtsch Dermatol Ges. 2010;8(Suppl2):S1–59.
   PubMedGoogle Scholar
• Le Cleach L, Lebrun-Vignes B, Bachelot A, et al. French acne guidelines working group and centre of evidence of dermatology. Guidelines for the management of acne: recommendations from a French multidisciplinary group. Br J Dermatol. 2017;177(4):908–913.
   PubMed Web of Science ®Google Scholar
• Hunt DW, Winters GC, Brownsey RW, et al. Inhibition of sebum production with the acetyl coenzyme A carboxylase inhibitor olumacostat glasaretil. J Invest Dermatol. 2017;137(7):1415–1423.
   PubMed Web of Science ®Google Scholar
• Ottaviani M, Alestas T, Flori E, et al. Peroxidated squalene induces the production of inflammatory mediators in HaCaT keratinocytes: a possible role in acne vulgaris. J Invest Dermatol. 2006;126(11):2430–2437.
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol. 2000;142(6):1084–1091.
   PubMed Web of Science ®Google Scholar
• Cunliffe WJ, Simpson NB. Disorders of the sebaceous gland. In: Champion RH, Burton JL, Burns DA, et al., editors. Textbook of dermatology. 6th ed. Oxford: Blackwell Science; 1998. p. 1927–1984.
   Google Scholar
• Janiczek-Dolphin N, Cook J, Thiboutot D, et al. Can sebum reduction predict acne outcome? Br J Dermatol. 2010;163(4):683–688.
   PubMed Web of Science ®Google Scholar
• Trifu V, Tiplica GS, Naumescu E, et al. Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol. 2011;165(1):177–183.
   PubMed Web of Science ®Google Scholar
• Lai JJ, Chan P, Lai KP. The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res. 2012;304(7):499–510.
   PubMed Web of Science ®Google Scholar
• Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 2001;116(5):793–800.
   PubMed Web of Science ®Google Scholar
• Kelce W Topical nitric oxide: a first-in-class local antiandrogen therapy for the treatment of acne and male pattern baldness. (White Paper). Novan Therapeutics. [cited 2018 Oct 30]. Available from: http://www.novan.com/files/8613/7398/9326/Topical_nitric_oxide_local_androgen_therapy.pdf
   Google Scholar
• Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgendependent skin disorders. Dermatology. 1996;193(3):177–184.
   PubMed Web of Science ®Google Scholar
• Chen W, Zouboulis CC. Hormones and the pilosebaceous unit. Dermatoendocrinol. 2009;1(2):81–86.
   PubMedGoogle Scholar
• Samson M, Labrie F, Zouboulis CC, et al. Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. J Invest Dermatol. 2010;130(2):602–604.
   PubMed Web of Science ®Google Scholar
• Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002;119(5):992–1007.
   PubMed Web of Science ®Google Scholar
• Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol. 2013;137:107–123.
   PubMed Web of Science ®Google Scholar
• Sansone G, Davidson W, Cummings B, et al. Sebaceous gland lipogenesis induced by testosterone: early metabolic events. J Invest Dermatol. 1971;57(3):144–148.
   PubMed Web of Science ®Google Scholar
• George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008;27(3):188–196.
   PubMed Web of Science ®Google Scholar
• Celasco G, Moro L, Bozzella R, et al. Biological profile of cortexolone 17alpha- propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881–886.
   PubMed Web of Science ®Google Scholar
• An evaluation of the adrenal suppression potential and pharmacokinetic properties of CB-03-01 crema in subjects with acne: Identifier NCT01831960 Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris: Identifier: NCT01631474. Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• An evaluation of the adrenal suppression potential and pk of cb-03-01 cream in pediatric patients with acne vulgaris: Identifier NCT02720627. Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A study to evaluate the safety and efficacy of cb-03-01 cream, 1% in subjects with facial acne vulgaris: Identifier NCT02608476 Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A study to evaluate the safety and efficacy of cb-03-01 cream, 1% in subjects with facial acne vulgaris: Identifier NCT02608450. Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Yang Z, Chang YJ, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. 2007;13(3):348–353.
   PubMed Web of Science ®Google Scholar
• Lai JJ, Lai KP, Chuang KH, et al. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest. 2009;119(12):3739–3751.
   PubMed Web of Science ®Google Scholar
• A phase 2 study of ASC-J9 cream in acne vulgaris. Identifier NCT00525499. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from:: www.clinicaltrials.gov
   Google Scholar
• Topical ASC-J9 cream for acne: Identifier NCT01289574. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Rosignoli C, Nicolas JC, Jomard A, et al. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Exp Dermatol. 2003;12(4):480–489.
   PubMed Web of Science ®Google Scholar
• Smythe CD, Greenall M, Kealy T. The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol. J Invest Dermatol. 1998;111(1):139–148.
   PubMed Web of Science ®Google Scholar
• Kim KH. Regulation of mammalian acetyl-coenzyme A carboxylase. Annu Rev Nutr. 1997;17:77–99.
   PubMed Web of Science ®Google Scholar
• Harwood HJ Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets. 2005;9(2):267–281.
   PubMed Web of Science ®Google Scholar
• Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci. 2005;62(16):1784–1803.
   PubMed Web of Science ®Google Scholar
• Melnick B. Olumacostat glasaretil,
a promising topical sebum-suppressing agent
that affects all major pathogenic factors of acne vulgaris. J Invest Dermatol. 2017;137(7):1405–1408.
   PubMed Web of Science ®Google Scholar
• Melnick B. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. Clin Cosmet Investig Dermatol. 2015;8:371–388.
   PubMed Web of Science ®Google Scholar
• McGarry JD, Brown NF. The mitochondrial carnitine palmitoyl-transferase system. From concept to molecular analysis. Eur J Biochem. 1997;244(1):1–14.
   PubMedGoogle Scholar
• Bissonnette R, Poulin Y, Drew J, et al. Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. J Am Acad Dermatol. 2017;76(1):33–39.
   PubMed Web of Science ®Google Scholar
• A safety, tolerability and preliminary efficacy study of DRM01B topical gel: Identifier NCT01936324 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A dose-ranging study of DRM01 in subjects with acne vulgaris: Identifier: NCT02431052 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A study of olumacostat glasaretil gel in subjects with acne vulgaris: Identifier: NCT03073486 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A study of olumacostat glasaretil gel in subjects with acne vulgaris: Identifier NCT03028363 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A long-term safety study of olumacostat glasaretil gel in subjects with acne vulgaris: Identifier: NCT03127956 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Del Rosso JQ, Stein-Gold L, Kircik L, et al. Olumacostat glasaretil (DRM01) for the treatment of acne vulgaris: primary results from the DRM01-ACN02 phase 2b randomized controlled trial. J Am Acad Dermatol. 2017;76(6Suppl 1):AB184.
   Web of Science ®Google Scholar
• Gribbon EM, Cunliffe WJ, Holland KT. Interaction of Propionibacterium acnes with skin lipids in vitro. J Gen Microbiol. 1993;139(8):1745–1751.
   PubMedGoogle Scholar
• McGinley KJ, Webster GF, Ruggieri MR, et al. Regional variations in density of cutaneous propionibacteria: correlation of Propionibacterium acnes populations with sebaceous secretion. J Clin Microbiol. 1980;12(5):672–675.
   PubMed Web of Science ®Google Scholar
• Thody AJ, Shuster S. Control of sebaceous gland function in the rat by alphamelanocyte-stimulating hormone. J Endocrinol. 1975;64(3):503–510.
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Sivarajah A, Gilliland Z, et al. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J Invest Dermatol. 2000;115(4):614–619.
   PubMed Web of Science ®Google Scholar
• Zhang L, Anthonavage M, Huang Q, et al. Proopiomelanocortin peptides and sebogenesis. Ann N Y Acad Sci. 2003;994:154–161.
   PubMed Web of Science ®Google Scholar
• Eisinger M, Li W-H, Anthonavage M, et al. A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011;63(1):23–32.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li W-H, Anthonavage M, et al. Melanocortin-5 receptor: a marker of human sebocyte differentiation. Peptides. 2006;27(2):413–420.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li WH, Anthonavage M, et al. Melanocortin-5 receptor and sebogenesis. Eur J Pharmacol. 2011;660(1):202–206.
   PubMed Web of Science ®Google Scholar
• A multi-center, double-blind, vehicle controlled, phase ii study of JNJ 10229570-AAA for the treatment of acne vulgaris. Identifier: NCT01326780 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Smith TM, Cong Z, Gilliland KL, et al. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response elementbinding protein-1. J Invest Dermatol. 2006;126(6):1226–1232.
   PubMed Web of Science ®Google Scholar
• Smith TM, Gilliland K, Clawson GA, et al. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3- kinase/Akt pathway. J Invest Dermatol. 2008;128(5):1286–1293.
   PubMed Web of Science ®Google Scholar
• Ristow HJ, Messmer TO. Basic fibroblast growth factor and insulin-like growth factor 1 are strong mitogens for cultured mouse keratinocytes. J Cell Physiol. 1988;137(2):277–284.
   PubMed Web of Science ®Google Scholar
• Krane JF, Murphy DP, Carter DM, et al. Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor I/somatomedin C (IGF-I) on keratinocyte proliferation may be mediated by IGF-I transmodulation of the EGF receptor. J Invest Dermatol. 1991;96(4):419–424.
   PubMed Web of Science ®Google Scholar
• Barreca A, De Luca M, Del Monte P, et al. In vitro paracrine regulation of human keratinocyte growth by fibroblast- derived insulin-like growth factors. J Cell Physiol. 1992;151(2):262–268.
   PubMed Web of Science ®Google Scholar
• Gilhar A, Ish-Shalom S, Pillar T, et al. Effect of antiinsulin-like growth factor
1 on epidermal proliferation of human skin transplanted onto nude mice treated with growth hormone. Endocrinology. 1994;134(1):229–232.
   PubMed Web of Science ®Google Scholar
• Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol. 2001;54(3):133–137.
   PubMedGoogle Scholar
• Sadagurski M, Yakar S, Weingarten G, et al. Insulin-like growth factor
1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol. 2006;26(7):2675–2687.
   PubMed Web of Science ®Google Scholar
• Melnik BC, Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol. 2009;18(10):833–841.
   PubMed Web of Science ®Google Scholar
• Alestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med. 2006;84(1):75–87.
   PubMed Web of Science ®Google Scholar
• Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–832.
   PubMed Web of Science ®Google Scholar
• Aizawa H, Niimura M. Elevated serum insulin-like growth factor-1 (IGF-1) levels in women with postadolescent acne. J Dermatol. 1995;22(4):249–252.
   PubMedGoogle Scholar
• Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol 76. 2005;141(3):333–338.
   PubMed Web of Science ®Google Scholar
• Vora S, Ovhal A, Jerajani H, et al. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol. 2008;159(4):990–991.
   PubMed Web of Science ®Google Scholar
• Isard O, Knol AC, Arie`S MF, et al. Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis
and induces keratinocyte proliferation. J Invest Dermatol. 2011;131(1):59–66.
   PubMed Web of Science ®Google Scholar
• Im M, Kim SY, Sohn KC, et al. Epigallocatechin-3-gallate suppresses IGF-1 induced lipogenesis and cytokine expression in SZ95 sebocytes. J Invest Dermatol. 2012;132(12):2700–2708.
   PubMed Web of Science ®Google Scholar
• Yoon JY, Kwon HH, Min SU, et al. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol. 2013;133(2):429–440.
   PubMed Web of Science ®Google Scholar
• Liao S. The medicinal action of androgens and green tea epigallocatechin gallate. Hong Kong Med J. 2001;7(4):369–374.
   PubMedGoogle Scholar
• Mahmood T, Akhtar N, Khan BA, et al. Outcomes of 3% green tea emulsion on
skin sebum production in male
volunteers. Bosn J Basic Med Sci. 2010;10(3):260–264.
   PubMed Web of Science ®Google Scholar
• Elsaie ML, Abdelhamid MF, Elsaaiee LT, et al. The efficacy of topical
2% green tea lotion in mild-to-moderate acne vulgaris. J Drugs Dermatol. 2009;8(4):358–364.
   PubMed Web of Science ®Google Scholar
• Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes: Identifier
NCT01687556. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Kwon HH, Yoon JY, Park SY, et al. Activity-guided purification identifies lupeol, a pentacyclic triterpene, as a therapeutic agent multiple pathogenic factors of acne. J Invest Dermatol. 2015;135(6):1491–1500.
   PubMed Web of Science ®Google Scholar
• Clinical study for the effectiveness and safety of topical lupeol in mild to moderate acne: Identifier: NCT02205892 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Clinical trial of lupeol for mild-moderate acne: Identifier NCT02152865 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713–3724.
   PubMed Web of Science ®Google Scholar
• A randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of BTX-1503 in patients with moderate to severe acne vulgaris: Identifier NCT03573518 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293–304.
   PubMed Web of Science ®Google Scholar
• Fisher GJ, Talwar HS, Xiao JH, et al. Immunological identification and functional quantification of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem. 1994;269(32):20629–20635.
   PubMed Web of Science ®Google Scholar
• Brand N, Petkovich M, Krust A, et al. Identification of
a second human retinoic acid receptor. Nature. 1988;332(6167):850–853.
   PubMed Web of Science ®Google Scholar
• Beard RL, Chandraratna RAS. RAR-selective ligands: receptor subtype and function selectivity. In: Nau H, Blaner WS, editors. Retinoids: the biochemical and molecular basis of vitamin A and retinoid action. Berlin: Springer; 1999. p. 185–213.
   Google Scholar
• Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10(9):940–954.
   PubMed Web of Science ®Google Scholar
• Endly DC, Miller RA. Oily skin: a review of treatment options. J Clin Aesthet Dermatol. 2017;10(8):49–55.
   PubMedGoogle Scholar
• Redfern CP, Todd C. Retinoic acid receptor expression in human skin keratinocytes and dermal fibroblasts in vitro. J Cell Sci. 1992;102(Pt1):113–121.
   PubMedGoogle Scholar
• Thoreau E, Arlabosse JM, Bouix-Peter C, et al. Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. Bioorg Med Chem Lett. 2018;28(10):1736–1741.
   PubMed Web of Science ®Google Scholar
• Aubert J, Piwnica D, Bertino B, et al. Nonclinial and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018;179(2):442–456.
   PubMed Web of Science ®Google Scholar
• A randomized, multi-center, investigator-blind, vehicle- and active-controlled, phase 2 study to assess the efficacy and safety of different concentrations of CD5789 cream applied once daily in subjects with moderate to severe acne vulgaris: Identifier: NCT01616654 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A long-term safety and efficacy study of CD5789 (trifarotene) 50 µg/g cream in subjects with acne vulgaris: Identifier NCT02189629 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A multi-center, randomized, double-blind, parallel-group vehicle controlled study to compare the efficacy and safety of CD5789 (trifarotene) 50µg/g cream versus vehicle cream in subjects with acne vulgaris: Identifier NCT02556788 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A multi-center, randomized, double-blind, parallel-group vehicle controlled study to compare the efficacy and safety of CD5789 (trifarotene) 50µg/g cream versus vehicle cream in subjects with acne vulgaris: Identifier NCT02566369 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Leyden JJ. The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg. 2001;20(3):139–143.
   PubMed Web of Science ®Google Scholar
• Cebrian R, Arevalo S, Rubiño S, et al. Control of Propionibacterium acnes by natural antimicrobiaL substances: role of the bacteriocin AS-48 and lysozyme. SciRep. 2018;8(1):11766.
   Google Scholar
• Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121(1):20–27.
   PubMed Web of Science ®Google Scholar
• Rosen T. The Propionibacterium acne genome: from the laboratory to the clinic. J Drugs Dermatol. 2007;6(6):582–586.
   PubMedGoogle Scholar
• Bruggemann H, Henne A, Hoster F, et al. The complete genome sequence of Propionibacterium acnes, commensal of the skin. Science. 2004;305(5684):671–673.
   PubMed Web of Science ®Google Scholar
• Sugisaki H, Yamanaka K, Kakeda M, et al. Increased interferon-gamma, interleukin-12p40 and IL-8 production in propionibacterium acnes-treated peripheral blood mononuclear cells from patient with acne vulgaris: host response but not bacterial species is the determinant factor of the disease. J Dermatol Sci. 2009;55(1):47–52.
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Katsambas AD. The role of propionibacterium acnes in acne pathogenesis: facts and controversies. Clin Dermatol. 2010;28(1):2–7.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Kircik LH. The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? J Drugs Dermatol. 2013;12(Suppl):109–115.
   Google Scholar
• Krause K, Schnitger A, Fimmel S, et al. Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands. Horm Metab Res. 2007;39(2):166–170.
   PubMed Web of Science ®Google Scholar
• Isard O, Knol AC, Castex-Rizzi N, et al. Cutaneous induction of corticotropin releasing hormone by propionibacterium acnes extracts. Dermatoendocrinol. 2009;1(2):96–99.
   PubMedGoogle Scholar
• Leyden JJ, McGinley KJ, Mills OH, et al. Propionibacterium levels in patients with and without acne. J Invest Dermatol. 1975;65(4):382–384.
   PubMed Web of Science ®Google Scholar
• Dreno B, Pecastaings S, Corvec S, et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. J Eur Acad Dermatol Venereol. 2018;32(Suppl. 2):5–14.
   PubMedGoogle Scholar
• Pecastaings S, Roques C, Nocera T, et al. Characterisation of Cutibacterium acnes phylotypes in acne and in vivo exploratory evaluation of Myrtacine. J Eur Acad Dermatol Venereol. 2018;32(Suppl. 2):15–23.
   PubMedGoogle Scholar
• Barnard E, Shi B, Kang D, et al. The balance of metagenomic elements shapes the skin microbiome in acne and health. Sci Rep. 2016;6:39491.
   PubMed Web of Science ®Google Scholar
• Szabo K, Erdei L, Bolla BS, et al. Factors shaping the composition of the cutaneous microbiota. Br J Dermatol. 2017;176(2):344–351.
   PubMed Web of Science ®Google Scholar
• Tan AW, Tan HH. Acne vulgaris: a review of antibiotic therapy. Expert Opin Pharmacother. 2005;6(3):409–418.
   PubMed Web of Science ®Google Scholar
• Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology. 2003;206(1):54–56.
   PubMed Web of Science ®Google Scholar
• Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148(3):467–478.
   PubMed Web of Science ®Google Scholar
• Dessinioti C, Katsambas A. Propionibacterium acnes and antimicrobial resistance in acne. Clin Dermatol. 2017;35(2):163–167.
   PubMed Web of Science ®Google Scholar
• Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002;146(5):840–848.
   PubMed Web of Science ®Google Scholar
• A randomized, multicenter, double-blind, placebo-controlledsStudy to evaluate the efficacy and safety of 1.5 mg/kg per day of sarecycline compared to placebo in the treatment of acne vulgaris: Identifier: NCT02320149 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A multi-center open-label evaluation of the safety of sarecycline tablets in the Treatment of acne vulgaris: Identifier: NCT02413346 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of 1.5 mg/kg per day of sarecycline compared to placebo in the treatment of acne vulgaris: Identifier NCT02322866 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Ramage G, Tunney MM, Patrick S, et al. Formation of propionibacterium
acnes biofilms on orthopaedic
biomaterials and their susceptibility to antimicrobials. Biomaterials. 2003;24(9):3221–3227.
   PubMedGoogle Scholar
• Burkhart CN, Burkhart CG. Microbiology’s principle of biofilms as a
major factor in the pathogenesis of acne
vulgaris. Int J Dermatol. 2003;42(12):925–927.
   PubMedGoogle Scholar
• Coenye T, Peeters E, Nelis HJ. Biofilm formation by Propionibacterium acnes is associated with increased resistance to antimicrobial agents and increased production of putative virulence factors. Res Microbiol. 2007;158(4):386–3892.
   PubMed Web of Science ®Google Scholar
• Green SJ, Mellouk S, Hoffman SL, et al. Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett. 1990;25(1–3):15–19.
   PubMed Web of Science ®Google Scholar
• Green SJ, Nacy CA, Schreiber RD, et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun. 1993;61(2):689–698.
   PubMed Web of Science ®Google Scholar
• Qin M, Landriscina A, Rosen JM, et al. Nitric oxide-releasing nanoparticles prevent propionibacterium acnes–induced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response. J Invest Dermatol. 2015;135(11):2723–2731.
   PubMed Web of Science ®Google Scholar
• Sokanovic SJ, Baburski AZ, Janjic MM, et al. The opposing roles of nitric oxide and cGMP in the age-associated decline in rat testicular steroidogenesis. Endocrinology. 2013;154(10):3914–3924.
   PubMed Web of Science ®Google Scholar
• Del Punta K, Charreau EH, Pignataro OP, et al. Nitric oxide inhibits Leydig cell steroidogenesis. Endocrinology. 1996;137(12):5337–5343.
   PubMed Web of Science ®Google Scholar
• Pomerantz D, Pitelka V. Nitric oxide is a mediator of the inhibitory effect of activated macrophages on production of androgen by the Leydig cell of the mouse. Endocrinology. 1998;139(3):922–931.
   PubMed Web of Science ®Google Scholar
• Drewett JG, Adams-Hays RL, Ho BY, et al. Nitric oxide potently inhibits the rate-limiting enzymatic step in steroidogenesis. Mol Cell Endocrinol. 2002;194(1–2):39–50.
   PubMed Web of Science ®Google Scholar
• A phase 1, single-center, open-label pharmacokinetic, safety and tolerability study of SB204 in adolescents with moderate to severe acne vulgaris: NCT02801903 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase 2, multi-center, randomized, evaluator-blinded, vehicle-controlled study comparing the efficacy, tolerability, and safety of SB204 gel and vehicle gel once or twice daily in the treatment of acne vulgaris: Identifier NCT02242760 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Baldwin H, Blanco D, McKeever C, et al. Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide-releasing drug for the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2016;9(8):12.
   PubMedGoogle Scholar
• Eichenfield LF, Gold WK, Cook-Bolden FE, et al. Results of a phase 2, randomized,vehicle-controlled study evaluating the efficacy,tolerability, and safety of daily or twice daily SB204 for the treatment of acne vulgaris. J Drugs Dermatol. 2016;15(12):1496–15027.
   PubMed Web of Science ®Google Scholar
• A phase 3 multi-center, open label study evaluating the long term safety of SB204 once daily in the treatment of acne vulgaris: Identifier NCT02798120 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase 3 multi-center, randomized, double-blinded, vehicle-controlled, parallel group study comparing the efficacy, tolerability and safety of SB204 and vehicle gel once daily in the treatment of acne vulgaris: Identifier: NCT02672332 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase 3 multi-center, randomized, double-blinded, vehicle-controlled, parallel group study comparing the efficacy, tolerability and safety of SB204 and vehicle gel once daily in the treatment of acne vulgaris: Identifier: NCT02667444 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison study to evaluate the safety and efficacy of UHE-101 cream 1% when applied twice daily for 12 weeks in subjects with facial acne vulgaris: Identifier NCT03307577 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• AAPPTEC. Safety Data Sheet. [cited 2018 Oct 30]. Available at: https://www.peptide.com/msds/MSDS%20UHE101%20H-beta-HGlu%20HCl.pdf
   Google Scholar
• Harder J, Tsuruta D, Murakami M, et al. What is the role of antimicrobial peptides (AMP) in acne vulgaris? Exp Dermatol. 2013;22(6):386–391.
   PubMed Web of Science ®Google Scholar
• Vaara M. New approaches in peptide antibiotics. Curr Opin Pharmacol. 2009;9(5):571–576.
   PubMed Web of Science ®Google Scholar
• Cotter P, Ross RP, Hill C. Bacteriocins — a viable alternative to antibiotics? Nat Rev Microbiol. 2013;11(2):95–105.
   PubMed Web of Science ®Google Scholar
• Montalban-Lopez M, Sanchez-Hidalgo M, Valdivia E, et al. Are bacteriocins underexploited? Novel applications for OLD antimicrobials. Curr Pharm Biotechnol. 2011;12(8):1205–1220.
   PubMed Web of Science ®Google Scholar
• Van Heel AJ, Montalban-Lopez M, Kuipers OP. Evaluating the feasibility of antibiotics as an alternative therapy against bacterial infections in humans. Expert Opin Drug Metab Toxicol. 2011;7(6):675–680.
   PubMed Web of Science ®Google Scholar
• Shin JM, Gwak JW, Kamarajan P, et al. Biomedical applications of nisin. J Appl Microbiol. 2016;120(6):1449–1465.
   PubMed Web of Science ®Google Scholar
• Melo MN, Dugourd D, Castanho MA. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Pat Antiinfect Drug Discov. 2006;1(2):201–207.
   PubMedGoogle Scholar
• Marta Guarna M, Coulson R, Rubinchik E. Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris. FEMS Microbiol Lett. 2006;257(1):1–6.
   PubMed Web of Science ®Google Scholar
• Pan CY, Chen JY, Lin TL, et al. In vitro activities of three synthetic peptides derived from epinecidin-1 and an anti-lipopolysaccharide factor against Propionibacterium acnes, Candida albicans, and Trichomonas vaginalis. Peptides. 2009;30(6):1058–1068.
   PubMed Web of Science ®Google Scholar
• Sader HS, Fedler KA, Rennie RP, et al. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother. 2004;48(8):3112–3118.
   PubMed Web of Science ®Google Scholar
• Rubinchik E, Dugourd D, Algara T, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009;34(5):457–461.
   PubMed Web of Science ®Google Scholar
• A phase 2, randomized, double-blind, vehicle-controlled, parallel group multicenter study to evaluate the safety and efficacy of CLS001 topical gel versus vehicle applied once daily for 12 weeks to female subjects with moderate to severe acne vulgaris: Identifier NCT02571998 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase ii, randomized, vehicle-controlled, double-blind, multi-center study to evaluate safety and efficacy of MBI 226 1.25% and 2.5% acne solutions applied topically for 12 weeks to subjects with acne vulgaris: Identifier NCT00211497 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• A phase 2, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of three once-daily CLS001 topical gels versus vehicle administered for 12 weeks to subjects with acne vulgaris: Identifier NCT02066545 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Deidda F, Amoruso A, Nicola S, et al. New approach in acne theraoy: a specific bacteriocin activity and a targeted IL-8 property in just 1 probiotic strain, the L. salivarius LS03. J Clin Gastroenterol. 2018;52(Suppl1):S78–S81.
   PubMedGoogle Scholar
• Faccone D, Veliz O, Corso A, et al. Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates. Eur J Med Chem. 2014;71:31–35.
   PubMed Web of Science ®Google Scholar
• Borunda JSA, Castro JARM, Santoyo PP, et al. Semi- solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne. Google Patents. 2016. [cited 2018 Oct 15]. Available from: https://patents.google.com/patent/US20160228424A1/en
   Google Scholar
• Ortega-Peña S, Hidalgo-Gonzalez C, Robson MC, et al. In vitro microbicidal, anti-biofilm and cytotoxic effects of different commercial antiseptics. Int Wound J. 2017;14(3):470–479.
   PubMed Web of Science ®Google Scholar
• Knuppel L, Ishikawa Y, Aichler M, et al. A novel antifibrotic mechanism of nintedanib and pirfenidone: inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol. 2017;57(1):77–90.
   PubMed Web of Science ®Google Scholar
• Molecular and clinical study of the effect of zaxcell versus effezel in the inflammatory and scarring process of moderate and severe acne: Identifier NCT03076320. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Nagy I, Pivarcsi A, Kis K, et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect. 2006;8(8):2195–2205.
   PubMed Web of Science ®Google Scholar
• Nagy I, Pivarcsi A, Koreck A, et al. Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and
interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol. 2005;124(5):931–938.
   PubMed Web of Science ®Google Scholar
• Studie van de huidmicrobiota en het potentieel van een crème met probiotica bij personen met acne: Identifier NCT03469076 Clinical Trials: A service of the U.S. National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Zouboulis C, Dessinioti D, Tsatsou F, et al. Anti-acne drugs in phase 1 and 2 clinical trials. Expert Opin Investig Drugs. 2017;26(7):813–823.
   PubMed Web of Science ®Google Scholar
• Bernhardt MJ, Myntti MF. Topical treatment with an agent disruptive to P. acnes biofilm provides positive therapeutic response: results of a randomized clinical trial. J Drugs Dermatol. 2016;15(6):677–683.
   PubMed Web of Science ®Google Scholar
• Next Science develops biofilm-fighting acne treatment gel-NextScience. [cited 2018 Oct 15]. Available from: https://www.nextscience.com/2016/05/01/next-science-develops-biofilm-fighting-acne-treatment-gel/
   Google Scholar
• Araviiskaia E, Dreno B. The role of topical dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016;30(6):926–935.
   PubMed Web of Science ®Google Scholar
• A multi-center, double-blind, vehicle-controlled study to evaluate the clinical effect of daily Next Science™ Acne gel (NAG) on mild to moderate facial acne: Identifier: NCT02404285 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Zouboulis CC. Leukotrien-antagonisten bei atopischen Erkrankungen und Akne. Akt Dermatol. 2003;29:419–425.
   Google Scholar
• Acebilustat (CTX-4430). CFF Clinical Trial Tools. [cited 2018 Oct 18]. Available from: https://www.cff.org/Trials/Pipeline/details/108/Acebilustat-CTX-4430
   Google Scholar
• Elborn JS, Bhatt L, Grosswald R, et al. Phase I studies of acebilustat: pharmacokinetics, pharmacodynamics, food effect, and cyp3a induction. Clin Transl Sci. 2017;10(1):20–27.
   PubMed Web of Science ®Google Scholar
• Alestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med (Berl). 2006;84(1):75–87.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Seltmann H, Alestas T. Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol. 2010;19(2):148–150.
   PubMed Web of Science ®Google Scholar
• A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris: Identifier: NCT02385760 Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high affinity monoclonal antibody for the treatment of IL-1b-mediated diseases. MAbs. 2011;3(1):49–60.
   PubMed Web of Science ®Google Scholar
• Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly. 2012;142:w13590.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Wanderer AA. Inflammasome and IL-1beta-Mediated Disorders. Curr Allergy Asthma Rep. 2010;10(4):229–235.
   PubMed Web of Science ®Google Scholar
• Sahdo B, Sarndahl E, Elgh F, et al. Propionibacterium acnes activates caspase-1 in human neutrophils. APMIS. 2013;121(7):652–663.
   PubMed Web of Science ®Google Scholar
• Kistowska M, Gehrke S, Jankovic D, et al. IL-1b drives inflammatory responses to propionibacterium acnes in vitro and in vivo. J Invest Dermatol. 2014;134(3):677–685.
   PubMed Web of Science ®Google Scholar
• Qin M, Pirouz A, Kim MH, et al. Propionibacterium acnes induces IL-1b secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol. 2014;134(2):381–388.
   PubMed Web of Science ®Google Scholar
• Avelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35(8):1654–1662.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? MAbs. 2013;5(1):1–4.
   PubMed Web of Science ®Google Scholar
• A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of gevokizumab in subjects with moderate to severe acne vulgaris Identifier NCT01498874. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• XOMA announces encouraging interim result from gevokizumab phase 2 study for moderate to severe acne vulgaris-Aktuell-Servier (Suisse) S.A. Conversum, Preterax, Fludex,Diamicron, Locabiotal, Arcalion, Daflon. [cited 2018 Oct 30]. Accessed from: https://www.servier.ch/de/aktuell/news-detail/2/xoma-announces-encouraging-interim-results-from-gevokizumab-phase-2-study-for-moderate-to-severe-acne-vulgaris/
   Google Scholar
• Walocko FM, Eber AE, Keri JE, et al. The role of nicotinamide in acne treatment. Dermatol Ther. 2017;30(5). Epub 2017 Feb 21. DOI:10.1111/dth.12481.
   PubMed Web of Science ®Google Scholar
• Grange PA, Raingeaud J, Calvez V, et al. Nicotinamide inhibits propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. J Dermatol ScI. 2009;56(2):106–112.
   PubMed Web of Science ®Google Scholar
• Fivenson DP. The mechanisms of action of nicotinamide and zinc in inflammatory skin disease. Cutis. 2006;77(1 Suppl):5–10.
   PubMedGoogle Scholar
• Wohlrab J, Kreft D. Niacinamide: mechanisms of action and its topical use in dermatology. Skin Pharmacol Physiol. 2014;27(6):311–315.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther. 2006;8(2):96–101.
   PubMedGoogle Scholar
• Shalita AR, Smith JG, Parich LC, et al. Topical nicotinamide compared with clindamycin gel in the treatmentof inflammatory acne vulgaris. Int J Dermatol. 2995;34(6):434–437.
   Google Scholar
• Khodaeiani E, Fouladi RF, Amirnia M, et al. Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris. Int J Dermatol. 2013;52(8):999–1004.
   PubMed Web of Science ®Google Scholar
• Morganti P, Beradesca E, Guarneri B, et al. Topical clindamycin 1% vs. linoleic acid-rich phosphatidylcholine and nicotinamide 4% in the treatment of acne: a multicentre-randomized trial. Int J Cosmet Sci. 2011;33(5):467–476.
   PubMed Web of Science ®Google Scholar
• Efficacy and tolerability of nicotinamide plus cream for moderate acne vulgaris in indonesia: a multicenter clinical trial: Identifier NCT03626298. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Sodium 3-[ethyl(3-methoxyphenyl)amino]-1-propanesulfonate. C12H18NNaO4S. ChemSpider. [cited 2018 Oct 30]. Accesed from: http://www.chemspider.com/Chemical-Structure.8119613.html?rid=6e6abbbd-1231-4cf5-a2b7-7ffa487b2fcf&page_num=0
   Google Scholar
• A multi-center, double-blind, randomized, placebo controlled, parallel-group study to evaluate the efficacy and safety of ADPS in the treatment of acne vulgaris: Identifier: NCT02935036 Clinical Trial: Identifier NCT03626298. Clinical Trials: A service of the U.S National Institutes of Health. [cited 2018 Oct 30]. Available from: www.clinicaltrials.gov
   Google Scholar
• Stein-Gold L, Weiss J, Rueda MJ, et al. Moderate and Severe Inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3%/benzoyl peroxide 2.5% gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17(3):293–303.
   PubMed Web of Science ®Google Scholar
• Dreno B, Tan J, Martel P, et al. Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial. J Eur Acad Dermatol Venereol. 2017;31(4):737–742.
   PubMed Web of Science ®Google Scholar
• Khalil S, Bardawil T, Stephan C. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28(8):684–696.
   PubMed Web of Science ®Google Scholar
• Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500–506.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Draelos Z, Lucky AW, et al. Preadolescent moderate acne
vulgaris: a randomized trial of the
efficacy and safety of topical adapalene-
benzoyl peroxides. J Drugs Dermatol. 2013;12(6):611–618.
   PubMed Web of Science ®Google Scholar
• Zeichner JA. Optimizing topical combination therapy for the treatment of acne vulgaris. J Drugs Dermatol. 2012;11(3):313–317.
   PubMed Web of Science ®Google Scholar
• Dreno B, Thiboutot D, Gollnick H, et al. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J dermatol. 2014;24(3):330–334.
   PubMed Web of Science ®Google Scholar
• Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005;153(2):395–403.
   PubMed Web of Science ®Google Scholar
• Zaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg. 2008;27(3):177–182.
   PubMed Web of Science ®Google Scholar
• Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361–372.
   PubMed Web of Science ®Google Scholar
• Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37(4):590–595.
   PubMed Web of Science ®Google Scholar
• Anderson KL, Dothard EH, Huang KE, et al. Frequency of primary nonadherence to acne treatment. JAMA Dermatol. 2015;151(6):623–626.
   PubMed Web of Science ®Google Scholar
• Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a ran- domized controlled trial. Cutis. 2010;86(2):103–108.
   PubMed Web of Science ®Google Scholar
• Tom WL, Barrio VR. New insights into adolescent acne. Curr Opin Pediatr. 2008;20(4):436–440.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Stein Gold L, Johnson SM, et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxyde 2.5% gel plus oral doxycycline in subjects with severe inflammatory acne who are candidate for Oral isotretinoin. J Drugs Dermatol. 2018 1;17(3):264–273.
   PubMed Web of Science ®Google Scholar
• Dreno B, Bisonnette R, Gagne-Henley A, et al. Prevention and reduction of atrophic scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized vehicle-controlled trial using intra-individual comparison. Am J Clin Dermatol. 2018;19(2):275–286.
   PubMed Web of Science ®Google Scholar
• Adler BL, Kornmehl H, Armstrong AW. Antibiotic resistance in acne treatment. JAMA Dermatol. 2017;153(8):810–811.
   PubMed Web of Science ®Google Scholar
• Kuet K, Fryatt E, Eady A, et al. Antibiotic resistance rates in cutaneous propionibacteria from UK patients with acne are not falling. Clin Exp Dermatol. 2018;43(4):467–468.
   PubMed Web of Science ®Google Scholar
• Nakase K, Nakaminami H, Takenaka Y, et al. Propionibacterium acnes is developing gradual increase in resistance to oral tetracyclines. J Med Microbiol. 2017;66(1):8–12.
   PubMed Web of Science ®Google Scholar